Patent Oppositions in antibodies industry

Explore the competitive field of antibodies where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in antibodies technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the antibodies industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the antibodies industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Aug 13, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 29, 2026STORZ
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 28, 2026PAJARO
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 27, 2026GREINER
Methods For Treating Cancer With Anti-Pd-1 AntibodiesMERCK SHARP & DOHMEJul 22, 2026ABBOTT PRODUCTION OPERATIONS
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 17, 2026POHLMAN
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 13, 2026MANZER
Methods Of Reducing Particle Formation And Compositions Formed TherebyREGENERON PHARMACEUTICALSJul 8, 2026HAMPTON KNOWLES
Pharmaceutical Compositions Comprising CabotegravirVIIV HEALTHCAREJun 19, 2026ELKINGTON AND FIFE
Compositions And Methods For Growth Factor ModulationSCHOLAR ROCKJun 16, 2026STRAWMAN
PolypeptidesSORRISO PHARMACEUTICALSJun 10, 2026SANOFI

To stay ahead in the competitive antibodies industry, companies are constantly innovating. Here are the top patents facing oppositions in the antibodies industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Aug 13, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Sep 19, 2018Methods Of Cell CultureMOMENTA PHARMACEUTICALS15
Jan 10, 2018Method To Improve Virus Removal In Protein PurificationF HOFFMANN LA ROCHE15
May 15, 2019Combination Therapy For The Treatment Of Ovarian CancerF HOFFMANN LA ROCHE12
Jan 13, 2021Method Of Treating Cancer Using Immune Checkpoint InhibitorBRISTOL MYERS SQUIBB11
Feb 17, 2021Pharmaceutical Composition For Cancer TreatmentSHIONOGI11
Feb 17, 2021Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of CancerLINDHOFER11
Feb 7, 2024Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R InhibitorREGENERON PHARMACEUTICALS10
May 15, 2019Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHE9
Oct 29, 2025Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBB9
May 1, 2019Combination Of Vaccination And Inhibition Of The Pd-1 PathwayCUREVAC8